--- title: "REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc" description: "Citadel Group disclosed its position regarding Mural Oncology PLC under Rule 8.3 of the Irish Takeover Panel. As of August 21, 2025, Citadel holds 403,916 relevant securities, representing 2.33% of Mu" type: "news" locale: "en" url: "https://longbridge.com/en/news/254196526.md" published_at: "2025-08-22T14:00:00.000Z" --- # REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc > Citadel Group disclosed its position regarding Mural Oncology PLC under Rule 8.3 of the Irish Takeover Panel. As of August 21, 2025, Citadel holds 403,916 relevant securities, representing 2.33% of Mural's common stock. The disclosure includes details of various transactions, including purchases and sales of common stock, as well as cash-settled and stock-settled derivatives. No indemnity or other dealing arrangements were reported. This disclosure is part of compliance with takeover regulations. RNS Number : 4280W Citadel Group 22 August 2025 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1\. KEY INFORMATION (a) Full name of discloser Citadel Group (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree MURAL ONCOLOGY PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) N/A (e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure 21 August 2025 (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" N/A 2\. INTERESTS AND SHORT POSITIONS If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security. Ap28 Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2) Class of relevant security (Note 3) Common Stock ISIN IE000LK2BOB4 $0.01 ordinary shares Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled 375,816 2.16 0 0.00 (2) Cash-settled derivatives 0 0.00 23 0.00 (3) Stock-settled derivatives (including options) and agreements to purchase/ sell 28,100 0.16 212,800 1.22 Total 403,916 2.33 212,823 1.22 All interests and all short positions should be disclosed. Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8. 3\. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4) Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (Note 5) Common Buy Transaction 62 2.0700 USD Common Buy Transaction 900 2.0711 USD Common Buy Transaction 12 2.0717 USD Common Buy Transaction 23 2.0717 USD Common Buy Transaction 250 2.0718 USD Common Buy Transaction 9 2.0722 USD Common Buy Transaction 1,884 2.0750 USD Common Buy Transaction 116 2.0751 USD Common Buy Transaction 3,106 2.0752 USD Common Buy Transaction 164 2.0787 USD Common Buy Transaction 20 2.0790 USD Common Buy Transaction 2,510 2.0800 USD Common Buy Transaction 20 2.0810 USD Common Buy Transaction 6,321 2.0816 USD Common Buy Transaction 357 2.0884 USD Common Buy Transaction 7,967 2.0900 USD Common Sell Transaction 2,133 2.0700 USD Common Sell Transaction 51,309 2.0701 USD Common Sell Transaction 15,114 2.0703 USD Common Sell Transaction 6,300 2.0708 USD Common Sell Transaction 9,969 2.0708 USD Common Sell Transaction 6,000 2.0708 USD Common Sell Transaction 3,652 2.0711 USD Common Sell Transaction 3,186 2.0713 USD Common Sell Transaction 1 2.0743 USD Common Sell Transaction 128 2.0750 USD Common Sell Transaction 47 2.0755 USD Common Sell Transaction 5 2.0760 USD Common Sell Transaction 40 2.0790 USD Common Sell Transaction 324 2.0793 USD Common Sell Transaction 424 2.0794 USD Common Sell Transaction 2,812 2.0800 USD Common Sell Transaction 100 2.0850 USD Common Sell Transaction 12 2.0883 USD Common Sell Transaction 160 2.0887 USD Common Sell Transaction 4,623 2.0888 USD Common Sell Transaction 575 2.0894 USD Common Sell Transaction 20 2.0895 USD Common Sell Transaction 471 2.0900 USD Ap29 (b) Cash-settled derivative transactions - Class of relevant security - Product description e.g. CFD - Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position - Number of reference securities (Note 6) - Price per unit (Note 5) (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying - Class of relevant security - Product description e.g. call option - Writing, purchasing, selling, varying etc. - Number of securities to which option relates (Note 6) - Exerciseprice per unit - Type e.g. American, Europeanetc. - Expiry date - Option moneypaid/ received per unit (ii) Exercise - Class of relevant security - Product description e.g. call option - Exercising/ exercised against - Number of securities - Exercise price per unit (Note 5) (d) Other dealings (including transactions in respect of new securities) (Note 3) - Class of relevant security - Nature of dealing e.g. subscription, conversion, exercise - Details - Price per unit (if applicable) (Note 5) Ap30 4\. OTHER INFORMATION (a) Indemnity and other dealing arrangements - Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" - None (b) Agreements, arrangements or understandings relating to options or derivatives - Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. - None (c) Attachments - Is a Supplemental Form 8 attached? - YES Date of disclosure 22 August 2025 Contact name Paula Santos Telephone number 020 7645 9700 Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service. Ap32 SUPPLEMENTAL FORM 8 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND RIGHTS TO SUBSCRIBE FOR NEW SECURITIES 1\. KEY INFORMATION Full name of person making disclosure: Citadel Group Name of offeror/offeree in relation to whose relevant securities the disclosure relates: MURAL ONCOLOGY PLC 2\. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS) Class of relevant security Product description e.g. call option Written or purchased Number of securities to which option or derivative relates Exercise price per unit Type e.g. American, European etc. Expiry date Common Put Option Purchased \-16,200 2.5 USD American 19/09/2025 Common Call Option Purchased 8,800 2.5 USD American 20/03/2026 Common Put Option Purchased \-200 5.0 USD American 19/09/2025 Common Call Option Purchased 800 5.0 USD American 19/12/2025 Common Call Option Purchased 900 5.0 USD American 20/03/2026 Common Put Option Purchased \-80,700 2.5 USD American 15/01/2027 Common Call Option Purchased 2,000 7.5 USD American 20/03/2026 Common Call Option Purchased 14,600 5.0 USD American 19/09/2025 Common Put Option Purchased \-3,100 2.5 USD American 19/12/2025 Common Put Option Sold 1,000 2.5 USD American 17/10/2025 Common Call Option Sold \-17,700 2.5 USD American 19/09/2025 Common Call Option Sold \-49,100 5.0 USD American 15/01/2027 Common Call Option Sold \-200 7.5 USD American 19/09/2025 Common Call Option Sold \-4,000 2.5 USD American 19/12/2025 Common Call Option Sold \-41,600 2.5 USD American 15/01/2027 3\. AGREEMENTS TO PURCHASE OR SELL Full details should be given so that the nature of the interest or position can be fully understood: Ap33 4\. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS) - Class of relevant security in relation to which subscription right exists: - Details, including nature of the rights concerned and relevant percentages: It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives. The currency of all prices and other monetary amounts should be stated. For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel. References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPPKBBPOBKKCFB ### Related Stocks - [MURA.US - Mural Oncology](https://longbridge.com/en/quote/MURA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/en/news/275997122.md) | | Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/en/news/275996849.md) | | Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/en/news/275995095.md) | | Klaveness Combination Carriers (OB:KCC) Net Margin Slide Challenges Bullish DCF Narrative | Klaveness Combination Carriers (OB:KCC) reported Q3 2025 revenue of US$64.5 million and EPS of US$0.20, with a trailing | [Link](https://longbridge.com/en/news/275992860.md) | | Aberdeen Group plc Has $144.09 Million Position in Arista Networks, Inc. $ANET | Aberdeen Group plc increased its stake in Arista Networks, Inc. by 1.4% in Q3, owning 1,005,027 shares valued at $144.09 | [Link](https://longbridge.com/en/news/275999141.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.